Article

Gleason Grade Progression Is Uncommon

Department of Pathology, Dana-Farber Cancer Institute, Boston
Cancer Research (Impact Factor: 9.33). 08/2013; 73(16):5163-5168. DOI: 10.1158/0008-5472.CAN-13-0427
Source: PubMed

ABSTRACT

Gleason grade is universally used for pathologic scoring of the differentiation of prostate cancer. However, it is unknown whether prostate tumors arise well differentiated and then progress to less differentiated forms or if Gleason grade is an early and largely unchanging feature. Prostate-specific antigen (PSA) screening has reduced the proportion of tumors diagnosed at advanced stage, which allows assessment of this question on a population level. If Gleason grade progresses as stage does, one would expect a similar reduction in high-grade tumors. We studied 1,207 Physicians' Health Study and Health Professionals Follow-up Study participants diagnosed with prostate cancer from 1982 to 2004 and treated with prostatectomy. We compared the distribution of grade and clinical stage across the pre-PSA and PSA screening eras. We re-reviewed grade using the ISUP 2005 revised criteria. The proportion of advanced stage tumors dropped more than six-fold, from the earliest period (12/1982-1/1993), 19.9% stage ≥T3, to the latest (5/2000-12/2004), 3% stage T3, none T4. The proportion of Gleason score ≥8 decreased substantially less, from 25.3% to 17.6%. A significant interaction between stage and diagnosis date predicting grade (P = 0.04) suggests that the relationship between grade and stage varies by time period. As the dramatic shift in stage since the introduction of PSA screening was accompanied by a more modest shift in Gleason grade, these findings suggest that grade may be established early in tumor pathogenesis. This has implications for the understanding of tumor progression and prognosis, and may help patients diagnosed with lower grade disease feel more comfortable choosing active surveillance. Cancer Res; 73(16); 5163-8. ©2013 AACR.

Download full-text

Full-text

Available from: Richard Flavin, Jan 15, 2016
  • Source
    • "In the current era of prostate-specific antigen (PSA) screening, nearly 90% of prostate cancers are clinically localized at the time of their diagnosis (Penney et al., 2013). The clinical behavior of localized prostate cancer is highly variable—while some men will have aggressive cancer leading to metastasis and death from the disease, many others will have indolent cancers that are cured with initial therapy or may be safely observed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defects.
    Full-text · Article · Nov 2015 · Cell
  • Source
    • "There is evidence that the clonal evolution model may hold true for some cancers however, a growing body of scientific evidence supports a hierarchical model for the majority of solid tumors [21]. For example, a recent study by Penny et al. looked at Gleason grade progression and found that even though PSA screening leads to a significant decrease of advanced prostate cancers, the Gleason grade did not follow this trend very closely, suggesting that in the vast majority of prostate cancers the most aggressive cell population arises early during cancer development [22] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the first prospective identification of cancer stem cells in solid cancers the cancer stem cell hypothesis has reemerged as a research topic of increasing interest. It postulates that solid cancers are organized hierarchically with a small number of cancer stem cells driving tumor growth, repopulation after injury and metastasis. They give rise to differentiated progeny, which lack these features. The model predicts that for any therapy to provide cure, all cancer stem cells have to be eliminated while the survival of differentiated progeny is less critical. In this review we discuss recent reports challenging the idea of a unidirectional differentiation of cancer cells. These reports provide evidence supporting the idea that non-stem cancer cells exhibit a remarkable degree of plasticity that allows them to re-acquire cancer stem cell traits, especially in the context of radiation therapy. We summarize conditions under which differentiation is reversed and discuss the current knowledge of the underlying mechanisms.
    Full-text · Article · Jul 2014 · Seminars in Cancer Biology
  • Source

    Preview · Article · Dec 2013 · Cancer
Show more